Strategic Financing AZTherapies has secured Series C-1 financing of 33.6 million and ongoing private funding, signaling strong investor confidence and a potential readiness to engage partners for late-stage trials, manufacturing scale-up, or strategic collaborations.

Leadership Alignment With a new CEO appointed in 2020 and a foundational leadership team plus an active Chief Scientific Officer, there is momentum for partnerships that leverage their neuroscience focus, translational biology capabilities, and potential co-development opportunities.

Neuroinflammation Focus The company targets neuroinflammation as a root cause of neurodegeneration using cromolyn, presenting a unique value proposition for collaborators or vendors offering CNS delivery, biomarker development, or companion diagnostics aligned with anti-inflammatory, neuroprotective strategies.

Clinical Progress As a late-stage clinical biopharma company with multiple candidates in Alzheimer’s, ALS, and post-ischemic cognitive impairment, there are opportunities to engage in CRO/CMO partnerships for pivotal trials, manufacturing scale, and regulatory strategy support.

Operational Footprint Small team size (2–10 employees) at a major Boston address indicates potential for high-touch vendor relationships in areas like manufacturing operations, CMC, clinical operations, data management, and specialized pharmacology services to accelerate milestones.